课题基金 / 基金详情

“NCI National Clinical Trials Network - Network Lead Academic Participating Sites”

“NCI National Clinical Trials Network - Network Lead Academic Participating Sites”
–NCI 国家临床试验网络 - 网络主导学术参与站点 –
批准号:
10734623
负责人:
Konstantin H. Dragnev
金额:
$19.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-11-04 至 2023-02-28

项目摘要

项目成果

Konstantin H. Dragnev的其他基金

相关文献

中文摘要
翻译
摘要 诺里斯·科顿癌症中心(NCCC),达特茅斯学院癌症相关活动的基石, 包括其盖泽尔医学院和达特茅斯-希区柯克健康公司,将参加NCI的全国 临床试验网络作为领先的学术参与网站。NCCC在这方面有着悠久的领导历史 国家合作小组临床试验,可追溯到CALGB的运营中心,以及更多 最近作为肿瘤学临床试验联盟、NRG、COG和ECOG/ACRIN的主要成员。AS NCCC是新英格兰北部唯一一家NCI指定的综合癌症中心,目前为 每年超过5,000名新患者和30,000名癌症回归患者。NCCC是专业学术中心 对于佛蒙特州和新罕布夏州,在该地区建立了一个由17个社区练习点组成的网络 以及接受罕见和晚期癌症的转诊,这是创新临床注册的目标人群 试验,从一个大的地理集水区。在达特茅斯,NCCC有一个中央临床办公室 协调所有可用的临床试验的全面参与的研究(OCR)。NCCC 打算全面参与NCTN的所有活动,扩大其先前对参与联盟的关注。 NCCC调查人员活跃在许多NCTN运营中心委员会,促进双向 将NCCC概念融入NCTN,同时NCTN研究将无缝地纳入NCTN NCCC试验组合。我们预计55名同意进行高绩效干预的受试者将获得应计利润 治疗试验和筛查的20名受试者仅为治疗或成像试验应计利润。卫生署的护理是 组织成17个指定的跨学科疾病团队,汇集了所有相关的 每周14个专科,适用于符合临床试验登记资格的新患者会议 是例行的评估。分配到这些临床肿瘤学小组(COG)的NCCC研究护士有 负责让团队了解可用的试验,以及NCCC临床试验的管理 该系统(Velos EResearch)为团队提供跟踪当前注册情况的报告。而最高优先级是 致力于将NCCC的科学转化为临床应用,达特茅斯的规模排除了大多数单一机构 研究和国家合作团体试验优先于行业发起的研究,以实现 NCCC的临床研究任务。
英文摘要
Abstract Norris Cotton Cancer Center (NCCC), the keystone of the cancer-related activities of both Dartmouth College, including its Geisel School of Medicine, and Dartmouth-Hitchcock Health, will participate in the NCI's National Clinical Trials Network as a Lead Academic Participating Site. NCCC has a long history of leadership in national cooperative group clinical trials, dating back to serving as an operating center for CALGB, and more recently as a main member of the Alliance for Clinical Trial in Oncology, NRG, COG, and ECOG/ACRIN. As the only NCI designated Comprehensive Cancer Center in northern New England, NCCC currently serves annually over 5,000 new patients and 30,000 returning cancer patients. NCCC is the specialty academic center for Vermont and New Hampshire, anchoring a network of 17 community-based practice sites across the region and receiving referrals of rare and advanced cancers, the target population for enrollment on innovative clinical trials, from a large geographic catchment area. Within Dartmouth, NCCC has a central Office of Clinical Research (OCR) which coordinates full participation in the entire range of available clinical trials. NCCC intends to participate fully in all NCTN activities, expanding its prior focus on participation in the Alliance. NCCC investigators are active in many NCTN Operations Center committees, facilitating a bi-directional integration of NCCC concepts into the NCTN, while NCTN studies will be seamless incorporated into the NCCC trial portfolio. We anticipate accrual of 55 consented subjects on high performance intervention for treatment trials and 20 subjects on screening only accruals for treatment or imaging trials. Care at DH is organized into 17 designated interdisciplinary disease-based teams which bring together all relevant specialties, 14 on a weekly basis, for new patient conferences at which eligibility for enrollment on clinical trials is assessed routinely. NCCC research nurses assigned to these Clinical Oncology Groups (COGs) are responsible for keeping the teams informed of available trials, and the NCCC clinical trials management system (Velos eResearch) provides the teams reports tracking current enrollment. While highest priority is given to translating NCCC science into clinical application, Dartmouth's size precludes most single-institution studies, and national cooperative group trials are prioritized ahead of industry-initiated studies for fulfillment of NCCC's clinical research mission.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1)
  • 批准号:
    10357862
  • 项目类别:
  • 资助金额:
    $17.25万
  • 财政年份:
    2019
  • 负责人:
    Konstantin H. Dragnev
  • 依托单位:
NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1)
  • 批准号:
    10116977
  • 项目类别:
  • 资助金额:
    $23.17万
  • 财政年份:
    2019
  • 负责人:
    Konstantin H. Dragnev
  • 依托单位:
NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1)
  • 批准号:
    9894768
  • 项目类别:
  • 资助金额:
    $32.19万
  • 财政年份:
    2019
  • 负责人:
    Konstantin H. Dragnev
  • 依托单位:
NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1)
  • 批准号:
    10581527
  • 项目类别:
  • 资助金额:
    $43.44万
  • 财政年份:
    2019
  • 负责人:
    Konstantin H. Dragnev
  • 依托单位: